Peptide-Protein Interactions

Overview

Many of the most important biological events — signal transduction, transcription, cell cycle control, immune recognition — are orchestrated by protein-protein interactions (PPIs). Unlike enzymes with deep, well-defined binding pockets, PPIs typically use flat, extended surfaces with dispersed hotspots, making them hard to drug with traditional small molecules. Peptides, which can match the shape, size, and binding chemistry of natural protein interfaces, are a natural modality for PPI inhibition.

This article surveys the landscape of peptide-protein interaction research, with an emphasis on PPI inhibitor design. For specific modalities see stapled peptides, cyclic peptides, and peptide aptamers.

Research Directions

Hotspot Identification

The starting point for most peptide PPI inhibitors is identifying the energetic hotspots on a protein interface — residues that contribute disproportionately to binding. Methods include:

• Alanine scanning mutagenesis to map contributions of individual residues.
• Computational hotspot mapping (FTMap, SiteMap).
• Hydrogen-deuterium exchange and NMR chemical shift perturbation.
• Structure-based identification from co-crystal structures or cryo-EM.

Once identified, short peptide sequences from the hotspot region — often 10-20 amino acids — serve as starting points.

Secondary Structure Mimics

Many protein interactions rely on secondary structure elements that can be mimicked by constrained peptides:

• α-Helical mimics — stapled peptides, β-peptides, and helix-constraining scaffolds used against MDM2-p53, BCL-2/BAX, and transcription factor interfaces. See stapled peptides.
• β-Strand mimics — β-sheet peptidomimetics and hairpin constraints.
• Reverse-turn mimics — cyclic peptides, β-hairpin peptides, and scaffolds that stabilize turn geometry. See cyclic peptides.
• PPII helical mimics — polyproline II structures common in SH3 and WW domain binding.

Library-Based Discovery

When no natural peptide lead exists, large peptide libraries are used:

• Phage display — presents billions of peptide variants on bacteriophage surfaces for selection against a protein target.
• mRNA display and RaPID — in vitro selection from even larger libraries, often with non-canonical amino acids.
• Yeast surface display.
• DNA-encoded peptide libraries.
• Computational de novo design using AI methods — see AI peptide discovery.

See peptide libraries for methodology.

Macrocyclic Peptides

Macrocyclic peptides — cyclic sequences of 8-14 amino acids — combine the binding diversity of peptides with improved cell permeability and proteolytic stability. RaPID-selected macrocycles have yielded PPI inhibitors against challenging targets including Ras, MDM2-MDMX, and various transcription factor interfaces.

Stapled and Stitched Peptides

Hydrocarbon stapling (all-hydrocarbon crosslinks between non-natural amino acids i, i+4 or i, i+7) constrains short peptides into their bioactive α-helical conformation, improving binding, proteolytic stability, and cell uptake. Stitched peptides use multiple staples to further constrain longer helices. These technologies have produced ALRN-6924 (MDM2/MDMX inhibitor) and numerous research tools. See stapled peptides.

β-Catenin, Ras, and Historically "Undruggable" Targets

Peptide approaches have made progress against targets long considered intractable for small molecules:

• Ras-effector interactions — peptide binders of Ras switch regions, and stapled peptides disrupting Ras-SOS interaction.
• β-Catenin-TCF — peptide inhibitors blocking Wnt transcriptional output.
• Transcription factor dimerization interfaces (STAT, c-Myc).
• KRAS-PDEδ — peptide disruptors.

Computational Design

De novo peptide design using Rosetta, AlphaFold2-based pipelines, and diffusion models (RFdiffusion) has dramatically accelerated the creation of peptide binders for defined protein targets. Designed miniprotein binders for SARS-CoV-2 spike protein were an early pandemic-era success.

PROTACs and Molecular Glues

Peptide-based PROTACs — heterobifunctional molecules that recruit E3 ligases to target proteins for degradation — exploit both sides of the PPI problem. The E3 recruiter can be peptidic, and the target-binding arm often is as well. See the ubiquitin-proteasome system mechanism article.

Methodological Considerations

Key methods:

• Biophysical characterization — SPR, ITC, BLI for affinity and kinetics.
• Cellular validation — NanoBiT complementation, fluorescence resonance energy transfer, target engagement assays.
• Structural determination — co-crystallography, cryo-EM, NMR for complex structures.
• In silico pipelines — docking, molecular dynamics, free energy perturbation.

Challenges that distinguish PPI inhibition from enzyme inhibition include weaker typical binding (μM rather than nM), slow kinetics, and the difficulty of confirming on-target cellular activity. See understanding peptide research, peptide history, and peptide safety.

Cell permeability remains the dominant obstacle for peptide PPI inhibitors targeting intracellular proteins. Strategies include macrocyclization, N-methylation, lipidation, and cell-penetrating peptide fusion. See oral peptide delivery and peptide bioconjugation.

Clinical Development

Clinical progress in peptide PPI inhibition includes:

• ALRN-6924 (MDM2/MDMX dual inhibitor stapled peptide) — in clinical trials for chemo-protection in p53-mutant tumors.
• Cilengitide (cyclic RGD peptide) — reached late-stage trials for glioblastoma as an integrin-PPI disruptor.
• Various macrocyclic peptide drugs in trials — for PD-1/PD-L1, PD-1/MEN1, and others.
• Selinexor — not a peptide but a PPI-style modulator of XPO1-cargo interaction, illustrating the broader PPI approach.

See drug development pipeline and clinical trial phases.

Safety and Limitations

Peptide PPI inhibitors face:

• Off-target PPI engagement — given the sometimes promiscuous nature of peptide binding.
• Pharmacokinetics — many macrocyclic peptides have challenging PK profiles.
• Manufacturing scale-up — complex modifications and stereochemistry increase cost.
• Immunogenicity for long-term use.

See peptide safety and stability challenges.

Future of the Field

Emerging themes:

• AI-designed miniproteins replacing classical peptide scaffolds.
• Cell-permeable macrocyclic drug classes reaching FDA approval.
• Peptide PROTACs and glues against currently undruggable targets.
• Peptide-drug conjugates combining PPI inhibition with cytotoxic payload delivery.

See future of peptides, AI peptide discovery, and peptide libraries.

Summary

Peptide-protein interaction research is the backbone of modern protein-protein interface drug discovery. Through advances in design, library screening, computational prediction, and peptide engineering, the field has made once-impossible targets accessible and continues to expand the therapeutic reach of peptides.